Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Apr 22;401(10385):1317-1319.
doi: 10.1016/S0140-6736(23)00803-6.

Even more benefit with endovascular treatment for patients with acute ischaemic stroke: MR CLEAN-LATE

Joanna M Wardlaw  1
Affiliations
Comment

Even more benefit with endovascular treatment for patients with acute ischaemic stroke: MR CLEAN-LATE

Joanna M Wardlaw. Lancet. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

I declare no competing interests. I receive research funding for work outside the topic discussed here from EU Horizon 2020, PHC-03-15, project number 666881, SVDs@target; the Fondation Leducq Transatlantic Network of Excellence for the Study of Perivascular Spaces in Small Vessel Disease, reference number 16 CVD 05; the Row Fogo Centre for Research into Ageing and the Brain, reference number AD.ROW4.35. BRO-D.FID3668413; the Stroke Association; the British Heart Foundation; and the UK Dementia Research Institute, which receives its funding from the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. I have had travel or accommodation costs reimbursed by scientific societies for whom I have given talks.

Comment on

  • Endovascular treatment versus no endovascular treatment after 6-24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial.
    Olthuis SGH, Pirson FAV, Pinckaers FME, Hinsenveld WH, Nieboer D, Ceulemans A, Knapen RRMM, Robbe MMQ, Berkhemer OA, van Walderveen MAA, Lycklama À Nijeholt GJ, Uyttenboogaart M, Schonewille WJ, van der Sluijs PM, Wolff L, van Voorst H, Postma AA, Roosendaal SD, van der Hoorn A, Emmer BJ, Krietemeijer MGM, van Doormaal PJ, Roozenbeek B, Goldhoorn RB, Staals J, de Ridder IR, van der Leij C, Coutinho JM, van der Worp HB, Lo RTH, Bokkers RPH, van Dijk EI, Boogaarts HD, Wermer MJH, van Es ACGM, van Tuijl JH, Kortman HGJ, Gons RAR, Yo LSF, Vos JA, de Laat KF, van Dijk LC, van den Wijngaard IR, Hofmeijer J, Martens JM, Brouwers PJAM, Bulut T, Remmers MJM, de Jong TEAM, den Hertog HM, van Hasselt BAAM, Rozeman AD, Elgersma OEH, van der Veen B, Sudiono DR, Lingsma HF, Roos YBWEM, Majoie CBLM, van der Lugt A, Dippel DWJ, van Zwam WH, van Oostenbrugge RJ; MR CLEAN-LATE investigators. Olthuis SGH, et al. Lancet. 2023 Apr 22;401(10385):1371-1380. doi: 10.1016/S0140-6736(23)00575-5. Epub 2023 Mar 29. Lancet. 2023. PMID: 37003289 Clinical Trial.

LinkOut - more resources